T-knife Therapeutics Announces Four Upcoming Data Presentations on PRAME-Targeted TK-6302 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

— Posters will review product characterization and manufacturing data on T-knife's lead program, TK-6302, a supercharged PRAME T cell receptor therapy that is advancing towards the clinic, with the filing of a Clinical Trial Application planned in Q4 2025 — PRAME is a validated target and is expressed in cancers of the skin, uterus, ovaries, […]

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care GlobeNewswire October 30, 2025 FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE, Inc. (“DefEYE”), a newly established

Next-Generation of Optical Ethernet PHY Transceivers Deliver Precision Time Protocol and MACsec Encryption for Long-Reach Networking

(NASDAQ:MCHP), CHANDLER, Ariz., Oct. 30, 2025 (GLOBE NEWSWIRE) — The rise of smart factories, remote monitoring and connected infrastructure are increasing the demand for advanced networking systems that can operate over long distances and in challenging environments. To address the need for reliable and secure connectivity solutions, Microchip Technology (Nasdaq: MCHP) today announces its new

Biomea Fusion to Present Poster Presentations at ObesityWeek(R)2025

Biomea Fusion to Present Poster Presentations at ObesityWeek(R)2025 GlobeNewswire October 30, 2025 SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present poster presentations at ObesityWeek(R) 2025, taking place November 4-7, 2025 in Atlanta, Georgia. The presentations

Lifetime Brands Announces Third Quarter 2025 Financial Results Release Date and Conference Call

(NASDAQ:LCUT), GARDEN CITY, N.Y., Oct. 30, 2025 (GLOBE NEWSWIRE) — Lifetime Brands, Inc. (NasdaqGS: LCUT) (the “Company”), a leading global designer, developer and marketer of a broad range of branded consumer products used in the home, will release its third quarter 2025 financial results before market open on Thursday, November 6, 2025. The Company will

SunPower Executes Major Sales Force Expansion Following Sunder Merger

SunPower Executes Major Sales Force Expansion Following Sunder Merger GlobeNewswire October 30, 2025 OREM, Utah, Oct. 30, 2025 (GLOBE NEWSWIRE) — SunPower Inc. (Nasdaq: SPWR) a solar technology, services, and installation company, this morning announced the successful integration of the Sunder salesforce into the company — as SunPower continues to execute on plan and expects

AllCloud Launches AI Fusion, a Multi-Layer Framework Delivering 70% Faster AI Deployments

DENVER, Oct. 30, 2025 (GLOBE NEWSWIRE) — AllCloud, a leading AI-first global cloud professional and managed services company, today announced the launch of AllCloud's AI Fusion. This powerful, multi-layer framework offers a scalable architecture and repeatable accelerators designed to revolutionize how organizations accelerate and achieve successful AI initiatives. AI Fusion is the foundational blueprint that

Altanine Strengthens Scientific Advisory Board with Appointment of Dr. Bruce D. Forrest

Altanine Strengthens Scientific Advisory Board with Appointment of Dr. Bruce D. Forrest Industry veteran brings decades of development experience to support Altanine's mission of advancing patient-focused drug-delivery innovation GlobeNewswire October 30, 2025 LOS ANGELES, Oct. 30, 2025 (GLOBE NEWSWIRE) — Altanine, a health innovation company dedicated to improving the comfort and convenience of everyday medicines

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

(NASDAQ:CTMX), SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a

Evaxion raises $7.2 million, extending cash runway to second half of 2027

(NASDAQ:EVAX), Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 million Total gross inflow of cash of $14.7 million since the end of the second quarter 2025 Evaxion now has cash on hand to fund its operations and R&D programs into the second half of 2027

Scroll to Top